273.4 is a legacy non-billable code used to specify a medical diagnosis of alpha-1-antitrypsin deficiency. This code was replaced on September 30, 2015 by its ICD-10 equivalent. The following crosswalk between ICD-9 to ICD-10 is based based on the General Equivalence Mappings (GEMS) information:
These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure. Alpha-1 antitrypsin deficiency is an inherited disorder that can cause lung disease in adults and liver disease in adults and children.
, if applicable, ligneous conjunctivitis (H10.51); Dysplasminogenemia; Hypoplasminogenemia; Type 1 plasminogen deficiency; Type 2 plasminogen deficiency; code for associated findings, such as:; hydrocephalus (G91.4); otitis media (H67.-); respiratory disorder related to plasminogen deficiency (J99) otitis media ( H67.-)
ICD-9-CM 273.4 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 273.4 should only be used for claims with a date of service on or before September 30, 2015.
ICD-10 Code for Alpha-1-antitrypsin deficiency- E88. 01- Codify by AAPC.
E88. 01 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Blood Tests and Lung Checks The best way to diagnose alpha-1 is a test that looks at your DNA (genetic information.) Your doctor will take a blood sample. Lab workers will check your sample for the faulty genes that cause alpha-1. Another blood test measures how much of the alpha-1 protein is in your body.
Alpha-1 antitrypsin deficiency (AAT deficiency) is an inherited condition that raises your risk for lung and liver disease. Alpha-1 antitrypsin (AAT) is a protein that protects the lungs. The liver makes it. If the AAT proteins aren't the right shape, they get stuck in the liver cells and can't reach the lungs.
The S allele is another, less common variant that causes ATTD. If a person inherits one M gene and one Z gene or one S gene ('type PiMZ' or 'type PiMS'), that person is a carrier of the disorder. While such a person may not have normal levels of alpha-1 antitrypsin, there should be enough to protect the lungs.
Alpha-1 is often first diagnosed as asthma or smoking-related Chronic Obstructive Pulmonary Disease (COPD). COPD includes emphysema and chronic bronchitis. Alpha-1 is the most common genetic risk factor for COPD. About 3 percent of all people diagnosed with COPD may have undetected Alpha-1.
Alpha-1 antitrypsin deficiency-associated lung disease is characterized by progressive degenerative and destructive changes in the lungs (emphysema, commonly of the panacinar type). Emphysema is a chronic, usually slowly progressive illness, which most commonly causes shortness of breath.
Alpha-1-Antitrypsin for Systemic Lupus Erythematosus (SLE) Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that affects millions of patients (mostly women) worldwide. SLE causes damage to multiple organs including kidney, brain, skin, and heart, and currently there is no cure for SLE.
Alpha-1 antitrypsin (AAT) is a laboratory test to measure the amount of AAT in your blood. The test is also done to check for abnormal forms of AAT.
What is an alpha-1 antitrypsin (AAT) test? This test measures the amount of alpha-1 antitrypsin (AAT) in the blood. AAT is a protein that is made in the liver. It helps protect your lungs from damage and diseases, such as emphysema and chronic obstructive pulmonary disease (COPD).
People with alpha-1 antitrypsin deficiency usually develop the first signs and symptoms of lung disease between ages 25 and 50. The earliest symptoms are shortness of breath following mild activity, reduced ability to exercise, and wheezing.
How does Alpha-1 lung disease affect my life expectancy? People who continue to smoke and have Alpha-1 lung disease, have an average life expectance of about 60 years of age.
Alpha-1 antitrypsin (aat) is a protein that protects the lungs. The liver usually makes the protein, and releases it into the bloodstream.
A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.
The 2022 edition of ICD-10-CM E88.01 became effective on October 1, 2021.